Monospecific antiserum to an unusually stable Mr 50,000 plasmmiogen-activator inhibitor (PAI) purified from cultured bovine aortic endothelial cells was employed in conjunction with reverse fibrin autography to determine whether human platelets, serum, and plasma contain immunologically related inhibitors. Reverse fibrin autography revealed the presence of a Mr 50,000 inhibitor in the platelet and serum samples but not in normal plasma. However, a Mr 50,000 inhibitor was detected in plasma obtained from individuals with increased PAI activity. In each case, treatment of
serum samples but not in normal plasma. However, a Mr 50,000 inhibitor was detected in plasma obtained from individuals with increased PAI activity. In each case, treatment of the sample with the anti-inhibitor serum removed the Mr 50,000 inhibitor. The inhibitor present in each sample neutralized exogenously added tissue-type plasminogen activator in a rapid manner. Inhibition was associated with the formation of a NaDodSO4-resistant enzyme-inhibitor complex of Mr 120,000. Again, treatment of the samples with the antiinhibitor serum removed both the inhibitory activity and the component in these samples that binds to tissue-type plasminogen activator. Thus, the rapidly acting PAI present in human platelets, serum, and patient plasma is immunologically related to the PAI synthesized by cultured bovine aortic endothelial cells. This molecule may be the physiologically relevant inhibitor of plasminogen activator in the vascular system and, as such, may serve an important role in regulating the initiation of vascular fibrinolysis.
Vascular thrombolysis may be initiated by tissue-type plasminogen activator (tPA; refs. 1-3) or urokinase-like plasminogen activator (4) (5) (6) , both of which convert the plasma zymogen, plasminogen, into the active, fibrin-degrading enzyme, plasmin. Conceptually, the activity of such plasminogen activators (PAs) may be regulated by specific inhibitors in the blood. Although plasminogen-activator inhibitor (PAI) activity has been detected in cultured endothelial cells (7) (8) (9) , platelets (10, 11) , and serum (12, 13) , initial reports failed to demonstrate its presence in normal human plasma (14) (15) (16) (17) (18) (19) (20) . However, several recent reports have now established the presence of such an activity in plasma from individuals at risk to develop thrombotic problems (21) (22) (23) (24) (25) . The relation between this plasma PAI and those previously detected in endothelial cells (7) (8) (9) , platelets (10, 11) , and serum (12, 13) has not been determined.
The objective of this study was to establish the biochemical and immunological relationship of these PAIs. Reverse fibrin autography (RFA; ref. 26) 
MATERIALS AND METHODS
Preparation of Serum, Plasma, and Platelets. Blood was collected from healthy volunteers into glass tubes and allowed to clot at 370C for 1 hr. The clot was removed by centrifugation at 1800 x g for 20 min at 40C, and the resulting serum was collected and stored at -70'C until used. To prepare platelet-rich plasma, the blood was collected into polypropylene tubes containing 3.8% (wt/vol) sodium citrate (pH 7.4) and was centrifuged at 200 x g for 15 min at 230C. The platelet-rich plasma was chilled to 40C for 15 min and then centrifuged at 1800 x g for 30 min at 40C to obtain platelet-poor plasma. Serum was prepared from these plasma samples by the addition of calcium and thrombin as described (11) . Plasma samples collected from patients and from healthy volunteers were obtained from B. Wiman (Karolinska Hospital, Stockholm, Sweden), and were prepared according to the methods used by Chmielewska et al. (22) . The results presented here were obtained using plasma obtained from individuals with obstetric complications (e.g., pre-eclampsia) and are representative of the results obtained using plasma samples collected from individuals at risk to develop thrombotic disease (21) (22) (23) (24) (25) . These samples contained 8-11 units of inhibitory activity/ml ofplasma, whereas normal samples contained little or no inhibitory activity (22) . Serum and patient plasma were "albumin-depleted" by precipitation with ammonium sulfate (25% saturation). The precipitate was resuspended in electrophoresis sample buffer (see below) to the original sample volume (100 tl) and then analyzed. Less than 20% of the total amount of albumin was precipitated under these conditions as determined by Coomassie blue staining of NaDodSO4/polyacrylamide gels.
Both gel-filtered platelets and the "releasates" obtained from thrombin-treated gel-filtered platelets (109 per ml) were prepared as described (11) .
Immunoadsorption of the PAL. Rabbit antiserum was prepared against purified BAE PAI according to published procedures (27) . This antiserum was shown to be monospecific for the BAE PAI both by immunoprecipitation of 3H-labeled BAE conditioned medium and by analysis of BAE conditioned medium by two-dimensional gel electrophoresis and immunoblotting (27) . It does not recognize a2-antiplasmin, the primary inhibitor of plasmin in blood. Either the antiserum (40 ,ul) , nonimmune serum (40 ,ul) , or buffer alone [40 ,ul, phosphate-buffered saline (Pi/NaCl, 0.14 M NaCl/10 mM sodium phosphate, pH 7.2)] was added to protein A-coated Sepharose CL-4B beads (80 ,ug; Pharmacia, Uppsala, Sweden) that had been rehydrated and washed ac-cording to the manufacturer's instructions. Samples of platelet releasate (100 Al), serum (35 dul), or patient plasma (35 1ul) were diluted into buffer, added to the beads, and then incubated at 230C for 1 hr in a total volume of 250 1.d. The beads were removed by centrifugation, the supernatant fluid was collected, and the beads were washed three times by centrifugation with 1 ml of Pi/NaCl and then extracted for 1 hr at 370C with 0.25 M TrisHCl, pH 6.8/2.2% NaDod-S04/20% (vol/vol) glycerol/0.025% bromophenol blue/2.5% (vol/vol) 2-mercaptoethanol. The resulting immunosupernatant fluids and/or the extracts from the immunoprecipitates then were assayed for PAI activity.
Assays for PAL. RFA was performed on NaDodSO4/polyacrylamide slab gels (9% resolving gel) as outlined previously (7, 26, 28) . Molecular weight standards were obtained from Bio-Rad and included carbonic anhydrase (Mr 31,000), ovalbumin (45,000), bovine serum albumin (66,200), and t3-galactosidase (116,250). These protein standards were fractionated electrophoretically in a lane of the gel separated from the other applied samples. This lane was then excised and stained with 0.1% Coomassie brilliant blue (Bio-Rad).
The following protocol was developed to examine the tPA-binding capacity of the samples. Platelet releasate, serum, and patient plasma, as well as the supernatant fluids obtained from the immunoprecipitations described above, were incubated for 10 min with 125I-labeled tPA. The mixtures then were fractionated by NaDodSO4/PAGE, and the gels were fixed in 10% acetic acid, dried, and subjected to autoradiography on Kodak X-Omat film for various times at -70°C. To quantitate the distribution of the 125I-labeled tPA, the individual lanes in the dried gel were removed and cut into 1-mm slices, and the radioactivity in each slice was determined by using a gamma counter (Micromedic Systems, Horsham, PA). The tPA was purified according to published procedures (2, 29) and was labeled with 1251 (Amersham) by the Iodogen method (30) , modified so that the labeling time was 3.5 min at 4°C. The specific activity of the final product was f5.3 x 106 cpm/,g of protein.
The inhibitory activity of the various samples was determined in the 1251-labeled fibrin plate assay by adding exogenous tPA (25 ,d, 2.5 milliunits) to 75 Al of appropriately diluted releasate, serum, or plasma. The mixtures were preincubated for 15 min, plasminogen was added (900 ul; final concentration, 4 ,ug/ml), and then the amount of fibrinolytic activity was determined as described (11) . The fibrinolytic activity in these mixtures was compared to that of control samples containing no inhibitor (i.e., containing tPA and plasminogen alone). Miscellaneous. Protein was determined by the method of Bradford (31) , with bovine serum albumin used as a standard. Plasminogen was prepared by affinity chromatography on lysine-Sepharose (32). Human a-thrombin was a gift from J. Fenton (New York State Department of Health, Albany, NY).
RESULTS
Comparison of the Molecular Weights of the Fibrinolytic Inhibitors in Platelets, Serum, and Plasma. Analysis of various blood-derived samples by RFA (Fig. 1) revealed the presence of fibrinolytic inhibitors in whole blood serum (lane 2) and in the plasma from a patient with pre-eclampsia (lane 5). However, these inhibitors exhibited lower apparent molecular weights than the inhibitor detected in platelet "releasate" (lane 1). This difference was attributed to the large amount of albumin present in the serum and plasma, since the inhibitor in these samples comigrated with the Mr 50,000 inhibitor in platelets when the albumin was removed (lanes 3 and 6). Thus, the inhibitors detected in human platelets, serum, and patient plasma had the same apparent molecular weight as the BAE PAI (7, 27) . This inhibitor was not detected in platelet-poor plasma obtained from healthy volunteers (lane 4).
Removal of the Fibrinolytic Inhibitors in Platelets, Serum, and Patient Plasma with Antiserum to the BAE PA. The immunologic relationship between the inhibitors in human platelets, serum, and patient plasma and the PAI recently purified from BAEs (27) was examined in immunoprecipitation experiments using antiserum directed against the BAE PAI (Fig. 2) . In each case, the Mr 50,000 inhibitor present in these samples (Fig. 2 A-C, lanes 1) was removed by the antiserum (lanes 2) and recovered in the immunoprecipitates (lanes 3) . No significant amount of inhibitor activity was immunoprecipitated from any of the samples when protein A-Sepharose containing nonimmune serum was used (data not shown). Thus, the inhibitors detected in platelets, serum, and patient plasma were related immunologically to the PAI synthesized by BAEs (7, 27) . Whereas immunoprecipitation did not alter the mobility of the platelet inhibitor ( Fig. 2A,   lanes 1 and 3) , it did alter the mobilities of the serum (B, lanes 1 and 3) and plasma (C, lanes 1 and 3) inhibitors. In both instances, the immunoprecipitated inhibitors migrated more slowly than the inhibitors in the starting materials. Moreover, they now comigrated with the platelet inhibitor. Again, this difference is consistent with the conclusion that the large amount of albumin present in the serum and plasma distorts the electrophoretic mobility of the inhibitor. This albumin is not present in the immunoprecipitates.
Complex Formation Between III-Labeled tPA and the PAI in Platelets, Serum, and Patient Plasma. The ability ofthe PAI in platelets to form NaDodSO4-stable complexes with tPA was investigated (Fig. 3) . The addition of 125"-labeled tPA (lane 1) to platelet releasate resulted in the formation of a complex of Mr -'120,000 (lane 2). A complex of the same molecular weight was evident when releasate that had been preadsorbed with nonimmune serum was used (lane 3). However, no Mr 120,000 complex was apparent when the releasate had been immunoadsorbed with antiserum against the BAE PAI (lane 4). Quantitation ofthe radioactivity in this gel indicated that the total counts (distributed as either free or complexed tPA) were essentially the same in each lane (data not shown).
When 125I-labeled tPA (Fig. 4A, lane 1) was added to serum (B, lane 1) or patient plasma (C, lane 1), Mr 120,000 complexes also formed (arrow). Again, complex formation was not affected by preadsorbing the samples with nonimmune serum (Fig. 4 B and C, lanes 2) but was completely prevented by immunoadsorbing the samples with the antiserum against the BAE PAI (B and C, lanes 3). The electrophoretic mobility of the free 125I-labeled tPA added to the serum and patient plasma was distorted by other proteins (e.g., albumin) present at high concentration in these samples. This conclusion is based on the finding that this same distorted pattern was apparent when serum was added to the labeled tPA under conditions that did not allow complex formation (i.e., in the presence of electrophoresis sample buffer; compare lanes 1 and 2 in Fig. 4A ). In spite of this distorted profile, the total radioactivity recovered from each lane was essentially the same (data not shown). No Mr 120,000 complex formed when either normal plasma or the serum derived from it was assayed in this manner (data not shown). Interestingly, a higher Mr complex (170,000-190,000) was also evident, but only in the immunodepleted samples (Fig. 4 B and C, lanes 3) . Based on previous reports (33, 34) ate, serum, and the patient plasma, the component that rapidly complexes with tPA is removed by the antiserum against the BAE PAL. Removal of this component coincides with the removal of the Mr 50,000 inhibitor detected in these samples by RFA (see Fig. 2 ).
Immunodepletion of tPA Inhibitory Activity from Platelets, Serum, and Patient Plasma. Although the antiserum directed against the BAE PAI removed both the Mr 50,000 inhibitor detected by RFA and the component that complexes with "251-labeled tPA, it was not clear how much of the total tPA inhibitory activity present in the various samples could be attributed to this component. Therefore, the total tPA inhibitory activity of the samples was assessed after they had been immunoadsorbed. Samples pretreated with protein A-Sepharose in the presence of buffer or nonimmune serum (Table  1) inhibited tPA-mediated fibrinolysis to a similar extent (70-80%). Samples pretreated with protein A-Sepharose in the presence of antiserum specific for the BAE PAI exhibited considerably less inhibition (10-30%6). Thus, removal of most of the tPA inhibitory activity present in each sample coincided with the removal of both the Mr 50,000 inhibitor (1985) detected by RFA and the component that forms Mr 120,000 complexes with 125I-labeled tPA. DISCUSSION In the work described here, we have employed RFA and monospecific antiserum directed against the BAE PAI to examine the relationship between the rapidly acting PAI synthesized by endothelial cells (7) (8) (9) 27) and those detected in platelets (10, 11) , serum (12, 13) , and the plasma of individuals at risk to develop thrombotic disease (21) (22) (23) (24) (25) . Three conclusions can be drawn from these studies. (i) The PAIs present in the blood-derived samples are biochemically similar to each other and to the BAE PAI, since each can be detected after NaDodSO4/PAGE and each has an apparent Mr of 50,000 ( Fig. 1; (Fig. 2) (11, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (33) (34) (35) . Thus, the residual antifibrinolytic activity remaining in the immunodepleted samples may be caused by plasmin inhibitors in addition to any PAIs not removed by the antiserum against the BAE PAT. We propose, therefore, that the Mr 50,000 PAI described in this report is the major inhibitor of tPA in the blood, whereas other PAIs may play important regulatory roles outside the vascular system and/or may be important inhibitors of vascular PA under certain other physiologic or pathologic conditions. Kruithofet al. (23) have provided evidence indicating that the primary plasma inhibitory activity against both urokinase and tPA resides in the same molecule. Thus, the PAI described here may also be the primary urokinase inhibitor in human blood.
Although PAI activities have been detected in a variety of human cells (7-9, 11, 36-40) and body fluids (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (33) (34) (35) , only three of these have been characterized sufficiently to allow a direct comparison with the PAI activity measured here. These include protease nexin (38) , the placenta-derived inhibitor (36) , and the dexamethasone-induced PAI synthesized by rat hepatoma cells (39) . Based on its unusual stability and immunologic properties, the PAI derived from endothelial cells and platelets described in this and other reports (7, 11, 27) clearly is not protease nexin or the placental inhibitor (ref. 27 and unpublished observations). The PAI synthesized by rat HTC cells is both acid-and NaDodSO4-stable (39) and, in these respects, is similar to the BAE PAI (7, 27) . Moreover, antiserum to the BAE PAI crossreacts with the HTC PAI (44) , indicating that these are also immunologically related molecules. The PAI synthesized by cultured rat granulosa cells is also immunologically related to the BAE PAI (40) , suggesting that this class ofPAIs may regulate a variety of processes involving plasminogen activation. The relationship of these PAIs to the PAIs elaborated by macrophages (37) , uterine cells (41) , and tumor cells (42) remains to be determined.
As to the physiologic role in blood of the PAI described here, we (11) and others (43) have suggested that the timely release of a rapidly acting PAI from platelets and/or endothelial cells may cause the environment surrounding a growing thrombus to be quite refractory to fibrinolysis, whether initiated by endogenous or infused PA. The detection of the platelet-derived PAI in serum (11) further suggests that the blood in the vicinity of a developing thrombus may be, at least transiently, antifibrinolytic. The primary vascular PAI may, therefore, prevent the premature lysis of blood clots. In addition, although we still do not know its precise site of origin, the presence of the PAI in the plasma of individuals with a tendency to develop thrombotic disease (21) (22) (23) (24) (25) suggests a possible relationship between these conditions and an overall decrease of the fibrinolytic potential of the blood.
